ArticleMedical oncology (Northwood, London, England)2013
Predictors and survival in patients with melanoma brain metastases.
Article in Medical oncology (Northwood, London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The association between graded prognostic assessment and the prognosis of brain metastases after whole brain radiotherapy: a meta-analysis.Frontiers in oncology · 2023Pooled it
- Evaluation of GPA, molGPA and prognostic factors in melanoma brain metastases: a single-center study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Single-cell transcriptomics and functional validation revealed PLEKHA5-L as a promoter of growth and migration in brain metastatic melanoma cells.Frontiers in oncology · 2025Article
- Whole-Body Magnetic Resonance Imaging (MRI) for Staging Melanoma Patients in Direct Comparison to Computed Tomography (CT): Results from a Prospective Positron Emission Tomography (PET)/CT and PET/MRI Study.Diagnostics (Basel, Switzerland) · 2023Article
- Immunotherapy in patients with brain metastasis: advances and challenges for the treatment and the application of circulating biomarkers.Frontiers in immunology · 2023Review
- Cost Analysis of Adjuvant Whole-Brain Radiotherapy Treatment Versus No Whole-Brain Radiotherapy After Stereotactic Radiosurgery and/or Surgery Among Adults with One to Three Melanoma Brain Metastases: Results from a Randomized Trial.PharmacoEconomics - open · 2022Article
- Whole-Body MRI for the Detection of Recurrence in Melanoma Patients at High Risk of Relapse.Cancers · 2021Article
- A Contemporary Report of Clinical Outcomes in Patients with Melanoma Brain Metastases.Current oncology (Toronto, Ont.) · 2021Article
- Review
- BRAF in malignant melanoma progression and metastasis: potentials and challenges.American journal of cancer research · 2020Review
- Temporal muscle thickness is an independent prognostic marker in melanoma patients with newly diagnosed brain metastases.Journal of neuro-oncology · 2018Article
- Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis.Melanoma research · 2017Article
- Brain metastasis: Unique challenges and open opportunities.Biochimica et biophysica acta. Reviews on cancer · 2017Review
- Linear accelerator-based stereotactic radiosurgery in 140 brain metastases from malignant melanoma.BMC cancer · 2015Article
- DNA methylation and gene deletion analysis of brain metastases in melanoma patients identifies mutually exclusive molecular alterations.Neuro-oncology · 2014Article
- Anatomical and topographical variations in the distribution of brain metastases based on primary cancer origin and molecular subtypes: a systematic review.Neuro-oncology advancesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain metastases (BM) are one of the most frequent neurological complications of cancers. Melanoma is the third most common tumor to metastasize to the brain with a reported incidence of 10-40 %, and many patients have subclinical BM (>73 %). We computer-searched the clinical records of all our patients registered into a database to identify patients that presented or developed BM. A total of 49 patients with melanoma BM were included in our analysis. General time to brain metastases (TTBM) was 23 months. The nonparametric test between TTBM and the single variables showed an association between TTBM and Breslow thickness (p < 0.0076; Spearman's coefficient-0.411), ulceration (p = 0.0656; Spearman's coefficient-0.287) and positive sentinel lymph node (p < 0.0015; Spearman's coefficient-0.475). Performing multiple regression, positive SLN remained the only, statistically significant, predictive variable (p < 0.01). Regarding the first melanoma site, the axial sites were more likely to develop BM than peripheral ones (p < 0.001). The analysis of brain metastasis survival (BMS) with Kaplan-Meier curves has resulted in a median survival rate of 6 months (range 1-134 months) and was strongly related to response to treatment, number of parenchymal lesions, presence or absence of symptoms. The results of the current analysis revealed clinical and primary tumor characteristics associated with the development of BM, TTBM, and BMS. The SNL was found to be the strongest predictor for BM development.
Indexed as
Identifiers
23377924What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.